MedTrace Logo

Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

NCT01514344 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-08-04

No results posted yet for this study

Summary

Phase II, monocentric, open label study to assess safety and activity of intralesional Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.

Conditions

  • Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma

Interventions

DRUG

intralesional rituximab

10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months

BIOLOGICAL

supplemental autologous serum

patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum

Sponsors & Collaborators

  • Andres J. M. Ferreri

    lead OTHER

Principal Investigators

  • Andrés JM Ferreri, MD · San Raffaele Scientific Institute, Milano, Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2014-10-31
Completion
2019-10-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01514344 on ClinicalTrials.gov